Bibliography
- Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
- Sokka T, Kautiainen H, Pincus T, et al. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis. 2009;68(11):1666–1672.
•• Indicates unmet need for inexpensive antirheumatic medications in many countries.
- Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354(9194):1932–1939.
- Brodszky V, Baji P, Balogh O, et al. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ. 2014;15(Suppl 1):S65–71.
•• Real-world estimation of benefits of biosimilars due to lower price
- Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613–1620.
• An original RCT of the biosimilar
- Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605–1612.
• An original RCT of the biosimilar
- Biosimilar monoclonal antibody approved in Korea/News/Biosimilars/Home - GaBI online - Generics and Biosimilars Initiative. [ cited 2015 Mar 9]. Available from: http://www.gabionline.net/Biosimilars/News/Biosimilar-monoclonal-antibody-approved-in-Korea.
- Espinosa Morales R, Díaz Borjón A, Barile Fabris LA, et al. Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012. Reumatol Clin. 2013;9(2):113–116.
- Fonseca JE, Gonçalves J, Araújo F, et al. The Portuguese Society of Rheumatology position paper on the use of biosimilars. Acta Reumatol Port. 2014;39(1):60–71.
- Atzeni F, Sebastiani M, Ricci C, et al. Position paper of Italian rheumatologists on the use of biosimilar drugs. Clin Exp Rheumatol. 2015;33(1):1–4.
- Position paper - Sweden [Internet]. 2015 [cited 2015 Mar 31]. Available from: http://www.svenskreumatologi.se/sites/default/file.
- Position paper - American College of Rheumatology [Internet]. 2015 [cited 2015 Mar 31]. Available from: https://www.rheumatology.org/Practice/Clinical/Pos.
- Position paper - BSR [Internet]. 2015 [cited 2015 Mar 31]. Available from: http://www.rheumatology.org.uk/about_bsr/press_rel.
- Sokka T, Haugeberg G, Pincus T. Assessment of quality of rheumatoid arthritis care requires joint count and/or patient questionnaire data not found in a usual medical record: examples from studies of premature mortality, changes in clinical status between 1985 and 2000, and a QUEST-RA global perspective. Clin Exp Rheumatol. 2007;25(6 Suppl 47):86–97.
- Baji P, Péntek M, Szántó S, et al. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. Eur J Health Econ. 2014;15(Suppl 1):S45–52.
- Dörner T, Strand V, Castañeda-Hernández G, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis. 2013;72(3):322–328.
- Park W, Miranda P, Brzosko M, et al. Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with ankylosing spondylitis: comparison between continuing with CT-P13 and switching from infliximab to CT-P13. Arthritis Rheum. 2013;65(12):3326.
- Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with rheumatoid arthritis: comparison between continued CT-P13 and switching from infliximab to CT-P13. Arthritis Rheum. 2013;65(12):3319.
- Putrik P, Ramiro S, Kvien TK, et al. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country’s wealth?. Ann Rheum Dis. 2014;73(11):2010–2021.
- Cornes P. The economic pressures for biosimilar drug use in cancer medicine. Target Oncol. 2012;7(Suppl 1):S57–67.
- Position paper Finland [Internet]. 2015 [cited 2015 Aug 31]. Available from: http://www.reumatologinenyhdistys.fi/files/sry-kannanotto-biosimilaarilaakkeisiin-050615.pdf.